New Randomized Double-Blind Trial in the Works With EGCG

Richard over at the DSTNI listserv, shared the following:

I just found out that a second and larger clinical trial has started in Spain. The dosage remains the same as in the pilot study, but this time the duration was set for 12 instead of only 3 months, and there are 100 participants ages 14 to 29yrs. First results are expected for December 2013.

The name of the clinical trial is: Normalization of dyrk1A and APP Function as an Approach to Improve Cognitive Performance and Decelerate AD Progression in DS Subjects: Epigallocatechin Gallate as Therapeutic Tool.

This is the brief summary and the goal of the study:

Epigallocatechin-3-gallate (EGCG), the major catechin in green tea, is postulated to modulate dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) and amyloid beta precursor protein (APP) gene overexpression in the brains of Down syndrome mouse models. The clinical study is aimed at demonstrating that normalization of Dyrk1A and APP functions is a therapeutic approach to improve cognitive performance and decelerate AD (Alzheimer's disease) like progression.

You can see the full clinical trial page at http://clinicaltrials.gov/ct2/show/record/NCT01699711.


Tweet